Curebase has added real-world data and artificial intelligence experts to its advisory board in a bid to capture a greater share of the decentralized trials market.
San Francisco-based Curebase has appointed Aaron Kamauu, M.D., managing director of real world data consultancy of Ikaika Health, and Amir Lahav, Sc.D., head of strategic R&D for digital healthcare innovation at Mitsubishi Tanabe Pharma Holdings.
Spokesman Shawn Malloy told Fierce Biotech the appointments would bolster Curebase’s decentralized clinical trial (DCT) offerings, citing the addition of Kamauu’s real-world data expertise.
“With his guidance we are hoping to incorporate the best in class RWE approaches into our DCT strategy to capture studies that rely heavily on this type of evidence from medical records, wearables, etc. and translate that specifically into global drug studies," Malloy said.
He also predicted Lahav’s digital health expertise and experience would be invaluable.
“With Amir's guidance we are taking our expertise in digital health to the next level by applying many of the techniques we use in global drug studies that present specific regional and drug related challenges he has experience with," Malloy said.
The global decentralized clinical trial market was worth $7.2 billion in 2019 and is growing 6.95% a year, according to recently published research.
The overall aim of the appointments is to build Curebase’s share of the sector Malloy said.
Curebase markets itself as an “end-to-end DCT provider,” providing a range of eClinical tools and clinical trial management systems as well as virtual “sites” that allow patients to take part remotely. The goal is to make research fully decentralized.
“We do this by activating local care centres, community clinics, drive through test sites, pharmacies, imaging centres where patients may need to be seen in-person, but allows them to participate in any clinical study in and around where they live without going far," Malloy said.